Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.42 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404012 | 0.93 | KMT2A (0.42) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL13103067 | 0.89 | KMT2A (0.41) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL3406802 | 0.82 | KMT2A (0.51) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL9679685 | 0.77 | SOAT1 (0.48) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL15327700 | 0.77 | KMT2A (0.40) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL9679354 | 0.75 | SOAT1 (0.47) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL9680743 | 0.75 | SOAT1 (0.51) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL9679702 | 0.73 | SOAT1 (0.49) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 | |
| SCHEMBL9679390 | 0.73 | ALDH1A1 (0.58) | KMT2AMEN1SMN1; SMN2SOAT2SOAT1 | |
| SCHEMBL12253101 | 0.73 | KMT2A (0.42) | KMT2AMEN1TDP1SMN1; SMN2SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197851-B1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | claimed |
| US-8513307-B2 | N-phenylacetamide inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | claimed |
| US-20100273813-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-28 | — | — | US | claimed |
| EP-2197851-A1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2010-06-23 | — | — | EP | claimed |
| WO-2009030750-A1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-12 | — | — | WO | claimed |
| EP-2197851-B1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8513307-B2 | N-phenylacetamide inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20100273813-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-28 | — | — | US | disclosed |
| EP-2197851-A1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030750-A1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273813-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, NAT1 | KMT2A 641/4885MEN1 4632/4885TDP1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.